The skin cancer chemotherapeutic agent ingenol-3-angelate (PEP005) is a substrate for the epidermal multidrug transporter (ABCB1) and targets tumor vasculature.
Ingenol-3-angelate (Ing3A), extracted from Euphorbia peplus, is currently in clinical trials for eradicating basal cell carcinoma, actinic keratosis, and squamous cell carcinoma (SCC) in situ by topical application. Although structurally related to phorbol esters and a protein kinase C activator, topical Ing3A, but not phorbol 12-myristate 13-acetate (PMA), inhibited the growth of subcutaneous tumors derived from PAM212 (mouse SCC) and B16 (mouse melanoma). Ing3A and PMA both induced acute neutrophilic inflammation on mouse skin, but only Ing3A caused subcutaneous hemorrhage and vascular damage. Both Ing3A and PMA activated extracellular signal-regulated kinase 1/2 (ERK1/2) in epidermis, but Ing3A also activated ERK1/2 in skin dermal fibroblasts and endothelial cells. Pretreatment with topical cyclosporin A (CsA), verapamil, or XR9576, modulators of P-glycoprotein (P-gp), prevented Ing3A-induced hemorrhage but not neutrophil infiltration. CsA also impaired the anticancer activity of Ing3A, whereas the anti-inflammatory dexamethasone did not. Ing3A, but not PMA, blocked photoaffinity labeling of human P-gp with [(125)I]iodoaryazidoprazosin and inhibited P-gp-mediated drug resistance to HCT-15 cells. The intracellular levels of Ing3A were significantly lower in P-gp-expressing cells, and treatment with XR9576 increased the levels to those of cells that do not express P-gp, showing that Ing3A binds to and is transported by P-gp. Taken together, our results suggest that P-gp-mediated absorptive transport, dermal penetration, and vascular damage contribute to the anticancer activity of Ing3A in vivo.
Li
Luowei
L
Laboratory of Cancer Biology and Genetics, Laboratory of Cell Biology, and Confocal Core Facility, Center for Cancer Research, National Cancer Institute and NIH Chemical Genomics Center, National Human Genome Research Institute, NIH, Bethesda, Maryland, USA.
Shukla
Suneet
S
Lee
Andrew
A
Garfield
Susan H
SH
Maloney
David J
DJ
Ambudkar
Suresh V
SV
Yuspa
Stuart H
SH
D018435:ATP Binding Cassette Transporter, Subfamily B; D020168:ATP Binding Cassette Transporter, Subfamily B, Member 1 / Q000037:antagonists & inhibitors / Q000378:metabolism*; D000287:Administration, Topical; D000818:Animals; D000970:Antineoplastic Agents / Q000378:metabolism* / Q000493:pharmacokinetics / Q000494:pharmacology; D002294:Carcinoma, Squamous Cell / Q000098:blood supply / Q000188:drug therapy / Q000378:metabolism; D045744:Cell Line, Tumor; D004224:Diterpenes / Q000378:metabolism* / Q000493:pharmacokinetics / Q000494:pharmacology; D003875:Drug Eruptions / Q000201:enzymology / Q000209:etiology; D004789:Enzyme Activation / Q000187:drug effects; D006801:Humans; D015603:Keratinocytes / Q000187:drug effects / Q000201:enzymology; D008546:Melanoma, Experimental / Q000098:blood supply / Q000188:drug therapy / Q000378:metabolism; D051379:Mice; D008807:Mice, Inbred BALB C; D008819:Mice, Nude; D009389:Neovascularization, Pathologic / Q000188:drug therapy / Q000378:metabolism; D011485:Protein Binding; D011493:Protein Kinase C / Q000378:metabolism; D012867:Skin / Q000187:drug effects / Q000201:enzymology; D012878:Skin Neoplasms / Q000098:blood supply / Q000188:drug therapy* / Q000378:metabolism*; D013755:Tetradecanoylphorbol Acetate / Q000494:pharmacology
C486592:3-ingenyl angelate; C513055:ABCB1 protein, human; D018435:ATP Binding Cassette Transporter, Subfamily B; D020168:ATP Binding Cassette Transporter, Subfamily B, Member 1; D000970:Antineoplastic Agents; D004224:Diterpenes; D011493:Protein Kinase C; D013755:Tetradecanoylphorbol Acetate
Biochim Biophys Acta. 2009 May;1794(5):860-71
19285158
Cancer Cell. 2005 May;7(5):411-23
15894262
Mol Cancer Ther. 2007 Jul;6(7):2092-102
17620438
Oncogene. 2006 Jan 19;25(3):378-86
16158048
Cancer Res. 1987 Jun 15;47(12):3174-9
3107806
Cancer Immunol Immunother. 2008 Aug;57(8):1241-51
18265980
Cancer Res. 2003 Oct 1;63(19):6547-55
14559850
Australas J Dermatol. 2009 Feb;50(1):16-22
19178487
J Invest Dermatol. 2001 Apr;116(4):541-8
11286621
Oncogene. 2003 Oct 20;22(47):7468-85
14576852
Cancer Res. 1980 Dec;40(12):4694-703
7438101
Cancer Res. 2004 Apr 15;64(8):2833-9
15087400
Nat Rev Clin Oncol. 2009 Sep;6(9):507-18
19636328
J Cell Physiol. 1995 Apr;163(1):105-14
7896886
Drug Metab Dispos. 2009 Feb;37(2):359-65
18971320
Nat Rev Cancer. 2008 Oct;8(10):743-54
18813320
Blood. 2005 Aug 15;106(4):1362-8
15845901
Carcinogenesis. 1989 Mar;10(3):531-40
2924397
Cancer Res. 1973 Mar;33(3):542-6
4689903
Am J Physiol. 1994 Sep;267(3 Pt 1):L223-41
7943249
J Immunol. 2005 Feb 1;174(3):1686-92
15661932
Mol Pharmacol. 2004 Mar;65(3):675-84
14978246
J Invest Dermatol. 2000 Jul;115(1):19-23
10886502
J Clin Invest. 2006 Oct;116(10):2757-66
16964312
J Invest Dermatol. 2008 Mar;128(3):643-54
17882268
J Natl Cancer Inst. 1973 Nov;51(5):1723-5
4762943
J Control Release. 2008 Nov 12;131(3):198-204
18725258
Cancer Res. 1981 May;41(5):1967-72
7214365
N Engl J Med. 2009 Sep 17;361(12):1202-5
19726764
Facial Plast Surg Clin North Am. 2009 Aug;17(3):309-24
19698913
Expert Rev Anticancer Ther. 2007 Apr;7(4):447-59
17428165
J Biol Chem. 1993 Dec 15;268(35):26079-81
8253722
J Control Release. 2010 Feb 15;141(3):277-99
19850095
J Investig Dermatol Symp Proc. 2002 Dec;7(1):17-26
12518788
J Biol Chem. 1998 Nov 6;273(45):29995-30002
9792720
Mol Cell Biol. 1999 Dec;19(12):8547-58
10567579
Cancer Res. 2004 May 1;64(9):3243-55
15126366
Science. 1986 May 2;232(4750):643-5
3457471
Int J Pharm. 2005 Nov 23;305(1-2):2-12
16246513
J Invest Dermatol. 2005 Jan;124(1):28-37
15654950
Mol Cancer Ther. 2004 Dec;3(12):1651-8
15634659
Carcinogenesis. 1993 Feb;14(2):205-9
8435862
J Immunol. 2006 Dec 1;177(11):8123-32
17114487
Semin Immunopathol. 2007 Apr;29(1):3-14
17621950